Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine

Summary

* This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine. * It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.

Eligibility

1. pancreatic cancer group

   Inclusion Criteria:
   * Pancreatic ductal adenocarcinoma that is pathologically confirmed or shows characteristic radiologic features
   * Patients with resectable pancreatic cancer at the time of surgery (Including borderline resectable pancreatic cancer at the time of diagnosis or Locally advanced pancreatic cancer after chemotherapy or radiation therapy)
   * Patients without invasion of adjacent organs other than the left adrenal gland and mesocolon
   * Patients with informed consent

   Exclusion Criteria:
   * History of other malignancy (Inclusive if there is no evidence of recurrence after 5 years of treatment)
   * Patient with Inflammatory disease(e.g. severe pancreatitis, cholangitis)
   * Patients with underlying diseases at high risk of general anesthesia
   * Other subject whom the investigator deems inappropriate
2. control group Inclusion Criteria included healthy individuals as well as patients with benign diseases.

Exclusion criteria for the control group included a previous cancer diagnosis within the past five years, active inflammatory diseases, borderline malignant pancreatic tumors, or a postoperative pathological finding of malignancy.

Conditions3

Browse More Trials